Sanofi and VIR Biotechnology signed an exclusive global license agreement for the PRO-XTEN platform.
1 report, 1 independent
Updated Jul 25
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Sanofi and VIR Biotechnology signed an exclusive global license agreement for the PRO-XTEN platform.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- VIR Biotechnology is developing TCEs targeting EGFR for solid tumors, specifically testing treatments for non-small cell lung cancer and colorectal cancer.Sub-event
Sanofi and VIR Biotechnology sign an exclusive global license agreement for the PRO-XTEN platform.1 source
Keep exploring
The entities involved
-
Sanofi
company in Milan, Italy
Nothing else this week.
-
VIR Biotechnology
biotech company
Nothing else this week.
Coverage
Newest first; wire copies grouped- Clinical Trials ArenaFirst subject dosed in Phase I trial of Vir Biotechnology’s VIR-5525 Vir Biotechnology has dosed the first subject in the non-randomised Phase I trial to assess VIR-5525, the investigational dual-mas